VGA039
Phase 1- Indications
- von Willebrand disease
Company intelligence / Profile preview
Vega Therapeutics
South San Francisco, California, United Statesstar-therapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Vega Therapeutics is conducting a Phase 1 clinical trial for VGA039, a first-in-class antibody therapy for von Willebrand disease. The FDA has granted orphan drug designation for VGA039. The ongoing Phase 1 study (NCT05776069) is evaluating safety, tolerability, pharmacokinetic, and pharmacodynamic profiles in healthy volunteers and VWD patients across sites in the EU and US.
- Therapeutic areas
- Hematology
- Modalities
- Monoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Vega Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vega Therapeutics.